Gold

Phase 3

Completed

• Conditions: Gastric Cancer

• Registration Number: JPRN-jRCT2080222339
• Lead Sponsor: Astrazeneca K.K

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-12-24
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Advanced gastric cancer (including GEJ) that has progressed following first-line therapy.

- Privision of tumour sample (from either a resection or biopsy).

- At least one lesion (measurable and/or non-measurable) that can be accurately assessed by imaging (CT/MRI) at baseline and following up visits.

Exclusion Criteria

- More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant chemotherapy with more than 6 month wash out period) for the treatment of gastric cancer in the advanced setting.

- Any previous treatment with a PARP inhibitor, including olaparib.

- Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for 5 years or more.

- HER2 positive patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival(OS)